Noah Goodman, MBA, is the Chief Business Officer at Kymera Therapeutics Inc., a clinical-stage biopharmaceutical company revolutionizing protein degradation therapies for immunology, oncology, and other diseases. In this pivotal role, Noah oversees all aspects of business development, strategic partnerships, corporate strategy, and investor relations, driving Kymera's mission to deliver first-in-class medicines through innovative degrader technologies. With over 15 years of experience in biotechnology and pharmaceuticals, Noah previously served as Senior Vice President of Business Development at Sanofi Genzyme, where he led high-impact transactions, including acquisitions, alliances, and licensing deals that expanded the company's oncology and rare disease portfolios. Earlier in his career, he was a biotech analyst and advisor at Leerink Partners (now SVB Leerink), focusing on M&A, financings, and equity research. Noah holds an MBA from Harvard Business School and a BA in Economics from Duke University. Under Noah's leadership, Kymera has secured transformative partnerships, such as multi-billion-dollar collaborations with Sanofi and GSK, fueling the advancement of its clinical pipeline, including KT-474 and KT-253. His strategic acumen has positioned Kymera as a leader in targeted protein degradation, enabling rapid growth and milestone achievements in a competitive biotech landscape.